The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the phase 3 program is and the primary indication is respiratory infection or all infection respiratory tract infections and patient population is 65 and up 65 and up so the first study that we're calling the program the protector program the first one is fully enrolled 1024 patients they're getting 16 weeks of drug treatment and we're following them for respiratory tract infections with sort of an electronic record that the patients fill out
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.